Preclinical characterization of CNS-active, mutant-selective fourth-generation EGFR inhibitors with potent activity against single, double, and triple mutant EGFR variants including T790M and C797S

MLA

S. Zhang, et al. “Preclinical Characterization of CNS-Active, Mutant-Selective Fourth-Generation EGFR Inhibitors with Potent Activity against Single, Double, and Triple Mutant EGFR Variants Including T790M and C797S.” European Journal of Cancer, vol. 174, Oct. 2022, p. S85. EBSCOhost, https://doi.org/10.1016/s0959-8049(22)01024-3.

APA

S. Zhang, W.S. Huang, S. Nadworny, E. Ye, N. Narasimhan, C.J. Eyermann, D. Dalgarno, V. Rivera, & W. Shakespeare. (2022). Preclinical characterization of CNS-active, mutant-selective fourth-generation EGFR inhibitors with potent activity against single, double, and triple mutant EGFR variants including T790M and C797S. European Journal of Cancer, 174, S85. https://doi.org/10.1016/s0959-8049(22)01024-3

Chicago

S. Zhang, W.S. Huang, S. Nadworny, E. Ye, N. Narasimhan, C.J. Eyermann, D. Dalgarno, V. Rivera, and W. Shakespeare. 2022. “Preclinical Characterization of CNS-Active, Mutant-Selective Fourth-Generation EGFR Inhibitors with Potent Activity against Single, Double, and Triple Mutant EGFR Variants Including T790M and C797S.” European Journal of Cancer 174 (October): S85. doi:10.1016/s0959-8049(22)01024-3.